The DRAM2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of DRAM2 in a near-haploid human myeloid leukemia background. This product consists of a heterogeneous pool of HAP1 cells that have undergone CRISPR/Cas9-mediated disruption of the DRAM2 gene, providing a physiologically relevant knockout model that avoids artifacts associated with clonal selection. The polyclonal format maintains genetic diversity while abolishing DRAM2 protein function, enabling robust assessment of autophagy and lysosomal pathways in a cell population context.
HAP1 cells are a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia line, isolated from the blast crisis phase. These adherent cells exhibit fibroblastoid morphology and possess a simplified, single-copy genomic structure that facilitates efficient CRISPR/Cas9 editing and straightforward genotype-phenotype analysis. The chronic myeloid leukemia origin makes the HAP1 background particularly relevant for investigating DRAM2-dependent processes in hematopoietic malignancies, where dysregulation of autophagy and lysosomal function contributes to disease progression and therapeutic resistance.
DRAM2 encodes a lysosomal membrane protein that is transcriptionally upregulated by TP53 in response to cellular stress, acting as a key downstream effector of p53-mediated autophagy. It promotes autophagosome-lysosome fusion and lysosomal acidification through interactions with LAMP1, LAMP2, and v-ATPase subunits, thereby driving autophagic flux and the degradation of cargoes such as damaged organelles and protein aggregates. DRAM2 functions within a signaling network that includes upstream regulators TFEB, DNA damage signals, and nutrient deprivation, while intersecting with the mTORC1 complex. Downstream, DRAM2 activation leads to MAP1LC3B lipidation and SQSTM1/p62 turnover, hallmark events in autophagy. This central position couples p53 stress signaling to lysosomal degradation, influencing cell fate decisions.
In the HAP1 leukemia model, DRAM2 knockout enables dissection of autophagy-dependent tumor suppression mechanisms. Chronic myeloid leukemia biology is intimately linked to p53 and autophagy pathway alterations during blast crisis progression. The near-haploid nature of HAP1 cells facilitates homozygous DRAM2 disruption without confounding diploid complementation, yielding a clean loss-of-function phenotype. This model allows researchers to investigate how DRAM2 deficiency impacts lysosomal acidification, autophagic clearance, and survival under chemotherapeutic stress, providing mechanistic insights into potential therapeutic resistance and oncogenic adaptation.
This polyclonal knockout cell population supports a wide array of experimental applications, including screening for autophagy modulators, validating DRAM2 as a therapeutic target in leukemia, and studying lysosomal dysfunction in cancer. Users can perform western blotting for LC3 and p62 to monitor autophagic flux, LysoTracker staining to assess lysosomal acidification, and autophagic flux assays with bafilomycin A1. Co-immunoprecipitation with LAMP1 confirms protein interactions, RT-qPCR measures p53 target gene induction, and flow cytometry quantifies apoptosis. For additional technical support or to explore custom applications, please contact Ascent Research.
